MindWalk Holdings Corp.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving MindWalk Holdings Corp. now
Current reporting with the operating signal separated from the noise.
MindWalk Holdings Corp. (HYFT) reports Q4 loss, misses revenue estimates
Investors are testing whether MindWalk Holdings Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
Investors are testing whether MindWalk Holdings Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 22, 2026
The story matters when it changes MindWalk Holdings Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
The story matters when it changes MindWalk Holdings Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MindWalk Holdings Corp.: MindWalk (NASDAQ: HYFT) Files Patent for High-Dimensional Biological Data Architecture Powering AI Drug Discovery
The development tests whether MindWalk Holdings Corp. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript
Investors are testing whether MindWalk Holdings Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened ...
Investors are testing whether MindWalk Holdings Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest HYFT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
MindWalk Holdings Corp., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →